Completed PHASE2 INTERVENTIONAL NCT00217282

Study of Oxaliplatin and Gemcitabine With or Without Bevacizumab to Treat Advanced Non-Small Cell Lung Cancer

Phase II Trial OF Oxaliplatin and Gemcitabine With Bevacizumab in Advanced Non-Small Cell Lung Cancer

Sponsor: Genentech, Inc.

Interventions oxaliplatin, gemcitabine, bevacizumab

Updated 6 times since 2017 Last updated: May 20, 2008 Started: Jun 30, 2004 Primary completion: Jun 30, 2007 Completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Non-Small Cell Lung Cancer, this trial is completed. The trial is conducted by Genentech, Inc. and has accumulated 6 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
Mt. Sinai Medical Center, Miami
Sanofi-Synthelabo

Data source: Mt. Sinai Medical Center, Miami

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami Beach, United States